Pharmaceutical company is building in the Breisgau industrial park.
The pharmaceutical company Losan Pharma is investing a middle double-digit million amount in a new administration building, a new production hall and – in the medium term – a new logistics center at its second location in the Breisgau industrial park. The symbolic groundbreaking ceremony started.
It is an ambitious project for Losan Pharma, a subsidiary of the “Dr. Falk Pharma” group in Freiburg. After Losan has long since reached its capacity limits at the Neuchâtel location, the expansion is now to take place at the second location in the business park. Losan acquired a 25,000 square meter property there in 2017 and has already put a production building into operation. Now the company wants to use reserves for the expansion.
The first thing to do is to build a new administration building that will accommodate 200 workplaces in the future. The building is to offer offices on three floors. A canteen is planned for the top floor, and there will be space for meeting rooms on the ground floor. A new production building with a 2000 square meter clean room area is to be attached to the administration building, which will mainly be used for the production of pharmaceuticals for the parent company Falk Pharma.
The administration building should be ready in the first half of 2023, construction of the new production building is scheduled to start next year, and it is scheduled to go into operation at the beginning of 2025. A new logistics center with a storage capacity of 15,000 pallet parking spaces is planned as the third building in the industrial park.
“Our shareholders and the management of the parent company supported the project from the start,” said Losan managing directors Thomas Andresen and Jens Morgenthaler at the groundbreaking ceremony. Andresen identified the need for the project in a few figures: “We have increased annual sales from 47 to 90 million euros today and the number of employees has increased from 400 to 600.” That is why one was increasingly reaching the limits of one’s capabilities. With a view to the high investment, Morgenthaler stated: “This is a courageous step to be able to guarantee the necessary growth.”
Two thirds for the parent company
The expansion is of enormous importance for Falk Pharma, explained one of the three Falk managing directors, Philipp Argast. Around 65 percent of the drugs produced by Losan are manufactured for the parent company. The increasing bottleneck in production has long been causing problems for the large sales growth.
The Falk managing director expects the new logistics center to concentrate storage capacities at just two locations. “It is an important and new chapter for the group of companies,” said Martin Falk from the entrepreneurial family.
–
